These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34560927)

  • 1. Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
    Li C; Li W; Dai S; Sharma A; Sharma HS; Wu Y
    Prog Brain Res; 2021; 265():407-414. PubMed ID: 34560927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
    Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
    Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
    Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
    Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
    Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
    Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with
    Liu R; Wei W; Hou H; Cong P; Zhou Y; Yu X
    Onco Targets Ther; 2022; 15():771-776. PubMed ID: 35847381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma.
    Li PJ; Lai SZ; Jin T; Ying HJ; Chen YM; Zhang P; Hang QQ; Deng H; Wang L; Feng JG; Chen XZ; Guo P; Chen M; Tian Y; Chen YY
    Radiother Oncol; 2023 Jun; 183():109633. PubMed ID: 36963438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
    Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of advanced ovarian cancer with anlotinib: a case report.
    Zhang P; Ma L; Wang X; Zhang R; Dong Y
    J Int Med Res; 2020 Dec; 48(12):300060520976824. PubMed ID: 33284728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
    Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
    Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
    Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
    Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review.
    Niu G; Wang H; Ren Y; Xing X; Zhao L; Liu N; Wen X; Zhai Y
    Immunotherapy; 2023 Aug; 15(12):905-912. PubMed ID: 37340883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
    Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.